Susan K Garwood1,1, Pam ClenDening1,1, Nathanael D Hevelone2,2, Kristin L Hood2,2, Sean Pidgeon2,2, Leonard James Wudel3,3. 1. Pulmonary Disease, 4230 Harding Road, Saint Thomas Health, Nashville, TN 37205, USA. 2. 710 Medtronic Parkway, Medtronic, Minneapolis, MN 55432, USA. 3. Thoracic Surgery, Medical Center Boulevard, Wake Forest Baptist Health, Winston Salem, NC 27157, USA.
Abstract
AIM: To evaluate the clinical and financial impact of introducing electromagnetic navigation bronchoscopy (ENB) at a community center. METHODS: This retrospective, single-arm, single-center study evaluated 90 consecutive patients who had undergone ENB in 2012. Radial probe endobronchial ultrasound was used to localize the lesion after initial ENB. ENB-aided diagnoses, follow-up procedures and treatments, and adverse events were collected through 2 years. RESULTS: ENB was conducted for lung biopsy (86 patients), fiducial placement (five), and/or dye marking (two). ENB-aided diagnostic yield was 82.6% (71/86), including 36 malignant and 35 nonmalignant cases. NSCLC was stage I-II in 84.6%. There were four false negatives. Sensitivity and negative predictive value were 90.0 and 88.6%. Pneumothorax occurred in 6/90 (5/6 with chest tube) and minor bleeding in four. The downstream revenue of new ENB cases was US$363,654. CONCLUSION: ENB introduction provided high diagnostic yield, early-stage diagnosis, acceptable safety, and was financially justified.
AIM: To evaluate the clinical and financial impact of introducing electromagnetic navigation bronchoscopy (ENB) at a community center. METHODS: This retrospective, single-arm, single-center study evaluated 90 consecutive patients who had undergone ENB in 2012. Radial probe endobronchial ultrasound was used to localize the lesion after initial ENB. ENB-aided diagnoses, follow-up procedures and treatments, and adverse events were collected through 2 years. RESULTS: ENB was conducted for lung biopsy (86 patients), fiducial placement (five), and/or dye marking (two). ENB-aided diagnostic yield was 82.6% (71/86), including 36 malignant and 35 nonmalignant cases. NSCLC was stage I-II in 84.6%. There were four false negatives. Sensitivity and negative predictive value were 90.0 and 88.6%. Pneumothorax occurred in 6/90 (5/6 with chest tube) and minor bleeding in four. The downstream revenue of new ENB cases was US$363,654. CONCLUSION: ENB introduction provided high diagnostic yield, early-stage diagnosis, acceptable safety, and was financially justified.
Authors: Ralf Eberhardt; Devanand Anantham; Armin Ernst; David Feller-Kopman; Felix Herth Journal: Am J Respir Crit Care Med Date: 2007-03-22 Impact factor: 21.405
Authors: D Makris; A Scherpereel; S Leroy; B Bouchindhomme; J-B Faivre; J Remy; P Ramon; C-H Marquette Journal: Eur Respir J Date: 2007-03-14 Impact factor: 16.671
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245